Is microRNA 1910-3p (miR-1910-3p) a really distinctive marker for psoriasis?

Background/aim: Although the cause of immune activation in the pathogenesis of psoriasis is still unclear, miRs are thought to have an effect on psoriasis. This work aimed to evaluate the role of miRs (miR-4649-3p, miR-6867-5p, miR-4296, miR-210, and miR-1910-3p) that target the FOXP3 mRNA and IL-17A mRNA in psoriasis. Materials and methods: Forty-four psoriasis patients and 44 healthy controls were included in the study. Quantitative real-time PCR (qRT-PCR) was used for the measurement of miRs. Serum IL-17A levels were determined by an enzyme-linked immunosorbent assay (ELISA) method. Results: Plasma miR-1910-3p levels were significantly lower in the patient group than the controls (P = 0.000, fc: 0.10). ROC analysis showed that plasma miR-1910-3p levels could significantly differentiate psoriasis patients from healthy controls [AUC = 0.912 (0.848– 0.975), P = 0.000]. The plasma miR-4649-3p level was significantly higher in the psoriasis group compared to the controls (P = 0.000, fc: 2.99). Conclusion: Decreased expression of miR-1910-3p increases the risk of developing psoriasis by approximately 50-fold and was able to use for the significant differentiation of psoriatic patients from healthy controls.Key words: Psoriasis, miR-1910-3p, IL-17A, regulatory T-cells

PDF

___

1. Bos JD, De Rie MA, Teunissen MBM, Psikin G. Psoriasis: dysregulation of innate immunity. British Journal of Dermatology 2005; 152 (6): 1098-1107. doi: 10.1111/j.1365- 2133.2005.06645.x
2. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. Journal of American Academy of Dermatology 2006; 54 (3): 67-80. doi: 10.1016/j. jaad.2005.10.057
3. Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y et al. ß-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis. Journal of Allergy and Clinical Immunology 2017; 139 (3): 923-932. doi: 10.1016/j. jaci.2016.06.038
4. Zhao M, Wang L, Liang G, Zhang P, Deng X et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4+ T cells of psoriasis vulgaris. Clinical Immunology 2014; 150 (1): 22-30. doi: 10.1016/j.clim.2013.10.009
5. Naveed A, Rahman S, Abdullah S, Naveed MA. A Concise review of microRNA exploring the insights of microRNA regulations in bacterial, viral and metabolic diseases. Molecular Biotechnology 2017; 59 (11-12): 518-529. doi:10.1007/s12033- 017-0034-7
6. Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L et al. Ultra-sensitive measurement of il-17a and il-17f in psoriasis patient serum and skin. The American Association of Pharmaceutical Scientists Journal 2017; 19 (4): 1218-1222. doi: 10.1208/s12248-017-0094-4
7. Fotiadou C, Lazaridou E, Sotiriou E, Gerou S, Kyrgidis A et al. IL-17A, IL-22, and IL-23 as markers of psoriasis activity: a cross-sectional, hospital-based study. Journal of Cutaneous Medicine and Surgery 2015; 19 (6): 555-560. doi: 10.1177/1203475415584503
8. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Archives of Dermatological Research 2012; 304 (6): 465-469. doi: 10.1007/s00403-012-1229-1
9. Caproni M, Antiga E, Melani L, Volpi W, Bianco ED et al. Serum Levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomizedcontrolled trial. Journal of Clinical Immunology 2009; 29 (2): 210-214. doi: 10.1007/s10875-008-9233-0
10. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clinical and Experimental Dermatology 2010; 35 (6): 645-649. doi: 10.1111/j.1365-2230.2009.03704.x
11. Arican O, Aral M, Sasmaz S, Ciragil P. Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17,and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of Inflammation 2005; 2005 (5): 273-279. doi: 10.1155/ MI.2005.273
12. Seifeldin NS, El Sayed SB, Asaad MK. Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris. International Journal of Dermatology 2016; 55 (11): 1242-1247. doi: 10.1111/ijd.13102
13. Ichihara A, Jinnin M, Oyama R, Yamane K, Fujisawa A et al. Increased serum levels of miR-1266 in patients with psoriasis vulgaris. European Journal of Dermatology 2012; 22 (1): 68-71. doi: 10.1684/ejd.2011.1600
14. Bian J, Liu R, Fan T, Liao L, Wang S et al. miR-340 Alleviates psoriasis in mice through direct targeting of IL-17A. Journal of Immunology 2018; 201 (5): 1412-1420. doi: 10.4049/ jimmunol.1800189
15. Elharrar E, Masalha M, Lerman G, Leibowitz-Amit R, Kassem R et al. Positive-negative feedback loop between miR-197 and IL-17A signaling in human keratinocytes. Immunome Research 2016; 12 (1): 1. doi: 10.4172/1745-7580.10000111
16. García-Rodríguez S, Arias-Santiago S, Blasco-Morente G, Orgaz-Molina J, Rosal-Vela A et al. Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity. Europan Academy of Dermatology and Venereology. 2017; 31 (2): 312- 322. doi: 10.1111/jdv.13861
17. Løvendorf MB, Zibert JR, Gyldenløve M, Røpke MA, Skov L. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. Journal of Dermatological Science 2014; 75 (2): 133-139. doi: 10.1016/j. jdermsci.2014.05.005
18. Zheng YZ, Chen CF, Jia LY, Yu TG, Sun J et al. Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris. Oncotarget 2017; 8 (31): 51288-51295. doi: 10.18632/ oncotarget.17260
19. Wang XY, Chen XY, Li J, Zhang HY, Liu J et al. MiR-200a expression in CD4+ T cells correlates with the expression of Th17/Treg cells and relevant cytokines in psoriasis vulgaris: a case control study. Biomedicine & Pharmacotherapy 2017; 93: 1158-1164. doi: 10.1016/j.biopha.2017.06.055
20. Pan X, Peng G, Liu S, Sun Z, Zou Z, Wu G. MicroRNA-4649- 3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells. International Journal of Molecular Medicne 2015; 36 (2): 559- 564. doi: 10.3892/ijmm.2015.2245
21. Budak F, Bal SH, Tezcan G, Akalın EH, Yılmaz A et al. The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity. PLOS ONE 2018; 13(6): e 0198659. doi: 10.1371/journal.pone.0198659
22. Wu R, Zeng J, Yuan J, Deng X, Huang YJ et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. The Journal of Clinical Investigation 2018; 128 (6): 2551-2568. doi: 10.1172/ JCI97426
23. Abdul-Maksoud RS, Sediq AM, Kattaia A, Elsayed W, Ezzeldin N et al. Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. British Journal of Biomedical Science 2017; 74 (4): 209-213. doi: 10.1080/09674845.2017.1343545
24. Park S, Lim W, Bazer FW, Whang KY, Song G. Quercetin inhibits proliferation of endometriosis regulating cyclin D1 and its target microRNAs in vitro and in vivo. The Journal of Nutritional Biochemistry 2019; 63: 87-100. doi: 10.1016/j. jnutbio.2018.09.024